Dental Products

Citagenix Catalogue
  • Accell Connexus®
  • The Accell process
  • The Accell advantage
  • Osteoinductive potential
  • Related documents

Accell Connexus®, Demineralized Bone Matrix Putty

Accell Connexus. Bone Grafting, Naturally™

          Incorporates:

          • Accell Technology

          • Isotis OrthoBiologics Processed DBM

          • 30% Poloxamer Reverse Phase Medium Carrier

          Benefits:

          • Validated Osteoinductive Potential

          • Poloxamer Reverse Phase Medium

            - Thickens at body temperature
            - Resists irrigation allowing for better graft containment
            - Is inert, biocompatible and safe

          • Moldable and easy to pack into virtually any size or shape defect

          • Ready to use

Available in 0.5, 1, 2.5, 5 and 10cc prefilled syringes

See our bone graft comparison chart page

The Accell ProcessThe Accell Process

Lot Division

Each donor lot of DBM is divided in two. Half is reserved for the final formulation.

Solubilization

The remaining half undergoes the Accell process which results in flowable carrier with osteoinductive potential.

Final Formulation

The flowable carrier is then combined with the DBM particles consisting of two components with osteoinductive potential.

E-Beam Sterilization

IsoTis OrthoBiologics terminally sterilizes every lot of Accell product with a low-dose electron beam, a process that has been demonstrated to preserve the osteoinductive potential of bone growth factors.

The Accell Advantage

Skeletally mature sheep model.

Cylindrical 5 mm metatarsal defect created in tibial diaphysis.

Results after 4 weeks

Control-Empty. Minimal bone regeneration observed at 4 weeks. Healing limited to area adjacent to host bone.Control - Empty

Minimal bone regeneration observed at 4 weeks. Healing limited to area adjacent to host bone.

1st Generation DBM. Bone regeneration occurs throughout the defect, caused by the presence of osteoinductive DBM particles. The inert carrier has been metabolized. (DynaGraft II®)1st Generation DBM

Bone regeneration occurs throughout the defect, caused by the presence of osteoinductive DBM particles. The inert carrier has been metabolized.
(DynaGraft II®)

Accell. Significantly more bone formation is evident immediately adjacent to the bone repair surfaces and within the interior of the defect. We believe this occurs because of the immediate access to the BMPs in the Accell products. (Accell 100™)Accell

Significantly more bone formation is evident immediately adjacent to the bone repair surfaces and within the interior of the defect. We believe this occurs because of the immediate access to the BMPs in the Accell products.
(Accell 100™)

Accell Bone Matrix's increased surface area provides access to natural bone proteins.
Natural bone protein content of ABM and particulate DBM was measured in vitro over time using an Enzyme Linked Immunosorbent Assay (ELISA). The results are shown graphically and indicate that bone protein was detectable in a saline solution containing ABM at earlier time points compared to that of particulate DBM.
The higher surface area and more open pore structure of ABM provides accessibility to the bone protein, without the need to be broken down. This analysis shows that while ABM provided early accessibility of natural bone protein, particulate DBM provides for accessibility of natural bone protein at later time points.